Pay in 4 interest-free payments of $6.79 Learn more
Ships within 48 hours · Estimated delivery Nov 6 - Nov 11
P., et al
Even if GLP-1s prove cost-saving over a members lifetime, plans may remain reluctant to cover them for two reasons
At the same time, payer policies often require discontinuation of GLP-1 therapy when a patients BMI drops below a set threshold, inadvertently triggering a frustrating cycle of weight loss and regainthe so-called yo-yo effect. This not only impacts ongoing adherence and persistence but also undermines the long-term cost-effectiveness of these therapies for healthcare systems
Two GLP-1R agonists have been approved in the United States to treat obesity: semaglutide and LIR, both of which are injected subcutaneously
A study of BRICS (Brazil, Russia, India, China, and South Africa) countries during 2007-2010 found that obesity was associated with hypertension, angina, diabetes, and arthritis (5)
Add to cart Sale
US$ 25.40
US$ 25.31
US$ 26.88
US$ 26.11
US$ 20.48
